Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29304013 | 0.90 | MAPT (0.39) | KMT2AMAPT | |
| SCHEMBL9545812 | 0.78 | TDP1 (0.49) | KMT2ATAAR1MAPT | |
| SCHEMBL11420525 | 0.77 | SCN8A (0.45) | MAPT | |
| SCHEMBL5541812 | 0.76 | MAOB (0.48) | MAOBKMT2AMEN1PPARAPPARD | |
| SCHEMBL11417644 | 0.75 | FFAR1 (0.55) | MAOB | |
| SCHEMBL22894152 | 0.74 | PPARA (0.54) | MAOBKMT2AMEN1PPARAPPARD | |
| SCHEMBL29304165 | 0.74 | MEN1 (0.44) | KMT2AMEN1PPARAPPARD | |
| SCHEMBL11959864 | 0.73 | TAAR1 (0.52) | MAOBKMT2AMEN1TAAR1 | |
| SCHEMBL506299 | 0.73 | CHRNB2 (0.42) | KMT2AMAPT | |
| SCHEMBL3335244 | 0.72 | MAPT (0.64) | KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | MAOB 943/4885KMT2A 2619/4885MEN1 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.